EGFR and non-small cell lung carcinoma: The integrin β1/SRC/AKT signaling pathway was identified as a key mediator of acquired resistance to gefitinib and erlotinib treatment in NSCLC harboring EGFR‐activating mutations; in addition, SRC activity contributes to anoikis resistance of human osteosarcoma cells (SAOS).